<DOC>
	<DOCNO>NCT01514357</DOCNO>
	<brief_summary>The aim study two fold : First investigator want determine safe effective dose subcutaneous ( SQ ) BNP subject resistant hypertension . Second , investigator want demonstrate efficacy chronically ( one week ) administer SQ BNP resistant hypertension reduce blood pressure .</brief_summary>
	<brief_title>Nesiritide Resistant Hypertension</brief_title>
	<detailed_description>Hypertension remain global burden cardiovascular disease lead stroke , myocardial infarction , heart failure . Its myocardial complication result increased mechanical load heart . Under physiological condition increase myocardial load result myocardial stretch , atrial natriuretic peptide ( ANP ) B-type natriuretic peptide ( BNP ) synthesis secretion occur contribute maintenance optimal cardiorenal blood pressure homeostasis . However , study indicate subject cardiovascular disease biological structure hormone may alter , thus reduce favorable protective activity . New study indicate early moderate hypertension associate derangement natriuretic peptide system characterize lack activation biologically active ANP BNP , severe hypertension characterize cardiac release alter molecular form ANP BNP reduce biological property and/or enhance degradation . The broad objective proposal advance biology therapeutic natriuretic peptide ( NPs ) special focus cardiac peptide BNP human hypertension . Our proposal base upon biological property BNP ( i.e. , natriuretic , renin-angiotensin-aldosterone suppressing , vasodilating , anti-fibrotic , anti-hypertrophic positive lusitropic ) , mechanistic role human hypertension , thus potential innovative chronic protein therapeutic enhance treatment patient uncontrolled resistant hypertension . Importantly , BNP endocrine hormone normally produce human heart , use therapeutic agent approve USA decade proven safe .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Inclusion criterion : Subjects resistant hypertension define Seventh Report Joint National Committee Prevention , Detection , Evaluation , Treatment High Blood Pressure ( JNC 7 ) guideline , systolic blood pressure and/or diastolic blood pressure &gt; 140/90 mm Hg . For patient hypertension diabetes renal disease , blood pressure &gt; 130/80 mm Hg despite treatment diuretic , sympathetic depressant vasodilator . Medications may include three drug regimen include : diuretic therapeutic dose second line agent sympatholytic ( e.g . betablockade , central agent clonidine ) angiotensin convert enzyme inhibitor ( ACEi ) / angiotensin receptor blocker ( ARB ) calcium channel blocker ( CCB ) . third line agent include one and/or direct vasodilator , hydralazine minoxidil . Exclusion criterion : Congestive Heart Failure ( NYHA class ) Ejection Fraction &lt; 50 % Known renal artery stenosis Myocardial infarction within 3 month screen Unstable angina within 14 day screen , evidence myocardial ischemia Moderate severe pulmonary hypertension Valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Sustained Atrial Fibrillation Second third degree AV block without permanent cardiac pacemaker Cerebral vascular accident within 3 month screen , evidence significantly compromised central nervous system perfusion Total bilirubin &gt; 1.5 mg/dL aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 1.5 time upper limit normal range Renal insufficiency assess calculated GFR &lt; 30 ml/min ( CockroftGault equation ) Serum sodium &lt; 125 mEq/dL &gt; 160 mEq/dL Serum potassium &lt; 3.0 mEq/dL &gt; 5.5 mEq/dL Women take hormonal contraceptive Pregnancy Body mass index ( BMI ) &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>